Past Speakers Include:

• 

  John Lambert EVP & CSO ImmunoGen John joined ImmunoGen in 1987. Prior to this, he was an Assistant Professor at Harvard Medical School. Dr. Lambert holds a Ph.D. in Biochemistry from University of Cambridge.

• 

  Manish Gupta Associate Director, Clinical Pharmacology & Pharmacometrics Bristol-Myers Squibb Prior to joining BMS, Manish was a scientist at Genentech, after a role as a Manager of Clinical Pharmacology at Pfizer. He received his PhD from the University of Tennessee.

• 

  Antonio Gualberto Group Head, Clinical Research Millennium Antonio is also an Adjunct Professor at Brown University. He has previously held positions at Pfizer and Case Western Reserve University.

• 

  David Satijn Associate Director Genmab Dr. David Satijn holds a PhD in Molecular Biology from the University of Amsterdam. In 2006, he joined Genmab and is currently supervising target discovery and novel antibody programs.

• 

  Mike Sun Associate Director Seattle Genetics Mike joined Seattle Genetics in 2000. He obtained his PhD in Chemical Engineering from the University of California, Berkeley.

• 

  Puja Sapra Director Pfizer Puja Sapra received a Bachelors degree from All India Institute of Medical Sciences, an MS in Pharmacology from University of Strathclyde, UK and a PhD in Pharmacology from University of Alberta, Canada. Read more...

• 

  Leonard Reyno Senior Vice President & CMO Agensys Prior to this, he served as the Senior Director at Cytokines, and a Medical Director at Genentech. He is also a Physician.

• 

  Ulrich Brinkmann Scientific Director Roche Ulrich leads a Protein Engineering unit within Roche Pharma Research in Penzberg, Germany. Prior to that, he served as CSO at Xantos and Epidauros.

• 

  Alain Beck Director, Physico-Chemistry Department Centre d’Immunologie Pierre Fabre Dr. Beck completed a BS in Biochemistry & a PhD in Bioorganic Chemistry at the University Louis Pasteur (Strasbourg, France, 1989). He then went to McGill University, Montreal, as a Post-doc (Merck-Frost fellow, 1989-90). Read more...

• 

  Alison Betts Senior Principal Scientist Pfizer Alison is a Senior Principal Scientist in the translational research group, department of pharmacokinetics, dynamics and metabolism at Pfizer Groton.

• 

  Abhijit Bhat Head of Research in Oncology CovX Research (Pfizer) Abhijit joined CovX in 2003 and helped establish and build the chemistry group at CovX. He has managed preclinical discovery programs in diverse disease areas such as wound healing, Diabetes, Pain, HIV and Oncology.

• 

  Mahendra Deonarain Reader in Antibody Technology Imperial College London Dr Deonarain obtained a first class degree in Biochemistry at Imperial College in 1988, and went on to Cambridge University in 1991 where he carried out his PhD research into enzyme protein engineering. Read more...

• 

  Vincent de Groot Vice President Synthon Vincent obtained his PhD from the Radboud University Nijmegen. He is a member of the AACR, ACS and LES. He holds a Certified Licensing Professional credential from LES.

• 

  William Olson Senior Vice President, R&D Progenics William C. Olson, Ph.D. joined Progenics Pharmaceuticals, Inc. in May 1994, serving in various roles of increasing responsibility through his promotion to Vice President, Research and Development in July 2008. Read more...

• 

  Feng Tian Associate Director, EuCode™ Technology Ambrx Dr. Tian has been with Ambrx for seven years. He led a team to establish Ambrx EuCodeTM platform which enables the site-specific incorporation of novel amino acids in mammalian cells. Read more...

• 

  Christoph Uherek Head of Preclinical Development, Biotherapeutics Biotest Christoph leads Biotest’s preclinical characterisation programs of mAbs and ADCs from mode of action to complete toxicological assessment. He has held previous positions at Ganymed Pharmaceuticals and the Georg-Speyer-Haus Institute. Read more...

• 

  Grazia Piizi Chemistry Project Leader Novartis Grazia Piizzi, currently Chemistry Leader of the Novartis ADC Platform. After my undergraduate studies in Pharmacy at the University of Rome, I moved to UCLA where I received my PhD in Organic Chemistry in 2004, working on the total synthesis of Ouabain. I then continued with a postdoctoral experience at MIT on the synthesis of a potent antitumor natural product: Irofulven. I joined Novartis Global Discovery Chemistry in 2006 and worked on several infectious disease, oncology and cardiovascular programs. Since 2009 I have been leading the medicinal chemistry team involved in the ADC program.

• 

  Andy Simmons Senior Scientist Associate Director Andy joined Takeda in 2009. He has previously held positions at Neugenesis and Cell Genesys, and obtained his PhD from the University of Texas Southwestern Medical Center.

• 

  Rajeeva Singh Director ImmunoGen Rajeeva obtained his Ph.D. in Organic Chemistry in 1990 at Harvard University. He has worked in several areas, including ADCs and an unconjugated anti-insulinlike growth factor I receptor antibody.

• 

  Tom Chittenden Executive Director, Research ImmunoGen Tom is responsible for managing Discovery and Cell Biology research programs at ImmunoGen. Tom received his Ph.D. in Molecular Biology from Princeton University and did post-doctoral research at Dana-Farber Cancer Institute in Boston.

• 

  Kedan Lin, Ph.D Group Leader Early Development PKPD Genentech Inc. Dr. Lin is a Scientist and Group Leader in Research and Early Development at Genentech. She received her Ph.D from University of California, San Francisco. Her research focuses on applying pharmacokinetic and pharmacodynamic principles in optimizing antibody drug conjugates and advancing clinical candidates.